In line with both Paweletz and colleagues18 and Ernst et al.,19 sensitivity for KRAS G12C ctDNA detection at baseline was approximately 70% in our study, which is in the range of ctDNA oncogene driver detection in patients with advanced NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.